| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
232,600,000 |
| Market
Cap: |
1.31(B) |
| Last
Volume: |
3,439,679 |
Avg
Vol: |
3,413,746 |
| 52
Week Range: |
$3.42 - $7.345 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile MannKind is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Co.'s primary product, Afrezza (insulin human) Inhalation Powder, is an inhaled insulin indicated to improve glycemic control in adults with diabetes. Afrezza consists of a dry powder formulation of human insulin delivered from a small portable inhaler. Co. collaborates with United Therapeutics to develop an inhaled formulation of treprostinil known as Tyvaso DPI.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
47,000 |
320,664 |
455,739 |
974,040 |
| Total Sell Value |
$250,980 |
$1,423,639 |
$2,345,526 |
$5,107,518 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
8 |
10 |
24 |
| End Date |
2025-08-10 |
2025-05-09 |
2024-11-08 |
2023-11-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Singh Sanjay R |
EVP Technical Operations |
• – – |
2025-10-31 |
4 |
D |
$5.59 |
$95,427 |
D/D |
(17,071) |
473,988 |
|
- |
|
| Tross Stuart A |
Chief People & Workpl Officer |
• – – |
2025-09-16 |
4 |
AS |
$5.34 |
$250,980 |
D/D |
(47,000) |
1,032,013 |
|
5% |
|
| Tross Stuart A |
Chief People & Workpl Officer |
• – – |
2025-08-05 |
4 |
A |
$3.92 |
$50,000 |
D/D |
12,755 |
1,079,013 |
|
- |
|
| Binder Steven B. |
|
– • – |
2025-07-16 |
4 |
AS |
$3.94 |
$296,946 |
D/D |
(75,367) |
830,508 |
|
42% |
|
| Thomson David |
EVP Genl Counsel & Secretary |
• – – |
2025-07-16 |
4 |
AS |
$3.94 |
$29,416 |
D/D |
(7,466) |
841,719 |
|
42% |
|
| Binder Steven B. |
|
– • – |
2025-07-15 |
4 |
D |
$3.85 |
$74,625 |
D/D |
(19,383) |
905,875 |
|
- |
|
| Castagna Michael |
Chief Executive Officer |
• • – |
2025-07-15 |
4 |
D |
$3.85 |
$428,409 |
D/D |
(111,275) |
2,504,792 |
|
- |
|
| Singh Sanjay R |
EVP Technical Operations |
• – – |
2025-07-15 |
4 |
D |
$3.85 |
$59,483 |
D/D |
(15,450) |
491,059 |
|
- |
|
| Sabella Lauren M |
EVP Operations |
• – – |
2025-07-15 |
4 |
D |
$3.85 |
$45,800 |
D/D |
(11,896) |
349,841 |
|
- |
|
| Blank Burkhard |
EVP Chief Medical Officer |
• – – |
2025-07-15 |
4 |
D |
$3.85 |
$36,791 |
D/D |
(9,556) |
460,791 |
|
- |
|
| Prentiss Christopher B |
Chief Financial Officer |
• – – |
2025-07-15 |
4 |
D |
$3.85 |
$44,429 |
D/D |
(11,540) |
343,854 |
|
- |
|
| Thomson David |
EVP Genl Counsel & Secretary |
• – – |
2025-07-15 |
4 |
D |
$3.85 |
$116,890 |
D/D |
(30,361) |
849,185 |
|
- |
|
| Tross Stuart A |
Chief People & Workpl Officer |
• – – |
2025-07-15 |
4 |
D |
$3.85 |
$108,019 |
D/D |
(28,057) |
1,066,258 |
|
- |
|
| Binder Steven B. |
|
– • – |
2025-06-10 |
4 |
AS |
$4.00 |
$256,340 |
D/D |
(64,085) |
925,258 |
|
40% |
|
| Blank Burkhard |
EVP Chief Medical Officer |
• – – |
2025-05-27 |
4 |
D |
$4.12 |
$64,396 |
D/D |
(15,630) |
465,124 |
|
- |
|
| Binder Steven B. |
|
– • – |
2025-05-20 |
4 |
AS |
$4.40 |
$53,143 |
D/D |
(12,078) |
989,343 |
|
24% |
|
| Thomson David |
EVP Genl Counsel & Secretary |
• – – |
2025-05-20 |
4 |
AS |
$4.41 |
$10,341 |
D/D |
(2,345) |
879,546 |
|
24% |
|
| Tross Stuart A |
Chief People & Workpl Officer |
• – – |
2025-05-19 |
4 |
D |
$4.37 |
$26,862 |
D/D |
(6,147) |
1,090,427 |
|
- |
|
| Binder Steven B. |
|
– • – |
2025-05-19 |
4 |
D |
$4.37 |
$22,680 |
D/D |
(5,190) |
1,001,421 |
|
- |
|
| Castagna Michael |
Chief Executive Officer |
• • – |
2025-05-19 |
4 |
D |
$4.37 |
$114,118 |
D/D |
(26,114) |
2,612,934 |
|
- |
|
| Thomson David |
EVP Genl Counsel & Secretary |
• – – |
2025-05-19 |
4 |
D |
$4.37 |
$41,672 |
D/D |
(9,536) |
881,891 |
|
- |
|
| Hooper Anthony C |
|
– • – |
2025-05-14 |
4 |
A |
$4.56 |
$114,000 |
D/D |
25,000 |
201,153 |
|
- |
|
| Castagna Michael |
Chief Executive Officer |
• • – |
2025-05-14 |
4 |
A |
$4.56 |
$123,120 |
D/D |
27,000 |
2,639,048 |
|
- |
|
| Marasco Dominic |
Pres, Endocrine Business Unit |
• – – |
2025-05-14 |
4 |
A |
$0.00 |
$99,996 |
D/D |
81,429 |
333,429 |
|
- |
|
| Thomson David |
EVP Genl Counsel & Secretary |
• – – |
2025-05-13 |
4 |
A |
$0.00 |
$0 |
D/D |
119,000 |
891,427 |
|
- |
|
365 Records found
|
|
Page 1 of 15 |
|
|
0.07 (1.23%) 
